The ABHD6 Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of human pancreatic cancer cells harboring a targeted disruption of the ABHD6 gene. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption without clonal isolation, yielding a heterogeneous knockout pool suitable for functional genomics studies. The polyclonal format preserves population-level complexity while enabling robust analysis of ABHD6-dependent phenotypes in a pancreatic ductal adenocarcinoma (PDAC) context.
The host cell line, PaTu 8988t, is an epithelial tumor cell line derived from a 64-year-old female patient with pancreatic ductal adenocarcinoma. It carries a KRAS G12V driver mutation and a TP53 mutation, recapitulating key genetic features of aggressive PDAC. These cells display characteristic epithelial morphology and serve as a widely used model for KRAS-driven pancreatic cancer research, including studies of tumor cell proliferation, invasion, and metabolic rewiring.
ABHD6 encodes a monoacylglycerol lipase that catalyzes the hydrolysis of the predominant endocannabinoid 2-arachidonoylglycerol (2-AG) into arachidonic acid and glycerol, thereby terminating endocannabinoid signaling. ABHD6 is regulated by upstream factors such as PPAR??, PPAR??, insulin, and free fatty acids, and its activity directly impacts downstream targets including cannabinoid receptors CB1 and CB2, arachidonic acid, prostaglandins, and other monoacylglycerols. It operates within a signaling network involving MAGL, cyclooxygenase (COX), and lipoxygenase (LOX) enzymes, placing it at the intersection of lipid metabolism and inflammatory signaling.
In the PaTu 8988t background, ABHD6 knockout is expected to elevate intracellular 2-AG levels, thereby potentiating cannabinoid receptor signaling and altering arachidonic acid-derived eicosanoid production. This perturbation can modulate key oncogenic pathways, potentially influencing cell proliferation, apoptosis, and metabolic reprogramming characteristic of KRAS-mutant PDAC. Given the role of endocannabinoid signaling in cancer cell metabolism and tumor microenvironment interactions, this model is valuable for dissecting ABHD6??s contribution to pancreatic cancer pathogenesis.
Researchers can employ these polyclonal knockout cells in a spectrum of functional assays, including cell viability (MTT or CellTiter-Glo), apoptosis detection (Annexin V/PI), transwell migration and invasion, and clonogenic survival. Downstream molecular analysis may involve Western blotting for p-ERK, AKT, and cleaved caspase-3, RT-qPCR profiling of endocannabinoid pathway genes, or LC-MS quantification of 2-AG and arachidonic acid. Additional applications include cAMP GloSensor assays for CB1 activity and gemcitabine drug sensitivity testing to explore ABHD6-dependent chemoresistance. For further information or technical support, please contact Ascent Research.
